Published June 4, 2024 | Version v1

The effects of PaPE-1 on amyloid beta-induced neurotoxicity

  • 1. Maj Institute of Pharmacology of Polish Academy of Sciences

Description

Data related to the article Posttreatment with PaPE-1 Protects from Aβ-Induced Neurodegeneration Through Inhibiting the Expression of Alzheimer's Disease-Related Genes and Apoptosis Process That Involves Enhanced DNA Methylation of Specific Genes. These are biochemical, molecular and microscopic data. We aimed to verify the neuroprotective capacity of PaPE-1 against amyloid beta (Aβ)-induced toxicity.  Fig 1 – the presence of amyloid beta in cellular cultures; Fig 2 – the effects of apoptosis inhibitors on amyloid beta-induced caspase-3 activity; Fig 3 – the effects of amyloid beta and PaPE-1 on caspase -3, -8, and -9 activities; Fig 4 – effects of amyloid beta and PaPE-1 on Calcein AM and Hoechst 33342 staining; Fig 5 – effects of amyloid beta and PaPE-1 on expression of apoptosis related factors; Fig 6 – effects of amyloid beta and PaPE-1 on methylation of specific genes; Fig 7 – effects of amyloid beta and PaPE-1 on the degree of neurodegeneration; Fig 8 - effects of amyloid beta and PaPE-1 on the membrane stain; Fig 9 - effects of amyloid beta and PaPE-1 on the expression of Alzheimer’s disease-related genes.

Files

fig 1.zip

Files (235.5 MB)

Name Size Download all
md5:f9a17adc7b93ca366775150f2021751f
235.4 MB Preview Download
md5:5fe9d1f15862c3dad4f3e90a80643dbe
13.5 kB Download
md5:4e6ebc534c1f5ededc3fe95063c2a7f0
44.5 kB Download
md5:24b7f6b3ca90ec0e4c5305abc33a6ed1
17.8 kB Download
md5:dec67ab4957ef58106d8e190b4083ce9
18.5 kB Download
md5:41200c86f43f2f0098422a13acf21a85
10.6 kB Download
md5:9b594741ca02cd1481f63aad94210f5b
18.8 kB Download
md5:be8748755693352d5c1c44312b437a5e
10.4 kB Download
md5:f1da2f5c75906b82f6b4ee30cae9e2b9
26.1 kB Download

Additional details

Related works

Is source of
Publication: 10.1007/s12035-023-03819-5 (DOI)

Funding

National Science Centre
Selective activation of non-nuclear Estrogen Receptor signaling with PaPE-1 as a novel therapeutic approach for sporadic Alzheimer’s Disease 2020/39/B/NZ7/00974